Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ibuprofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 5/20 | 1.00 |
| ▸ | PTGS2 known ✓ | P35354 | 5/20 | 1.00 |
| ▸ | CXCR1 | P25024 | 5/20 | 1.00 |
| ▸ | CXCR2 | P25025 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 2/20 | 1.00 |
| ▸ | ALB | P02768 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 1/20 | 1.00 |
| ▸ | RARB | P10826 | 1/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | NR1I3 | Q14994 | 1/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 1.00 |
| ▸ | CXCL8 | P10145 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | AKR1C2 | P52895 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ibuprofen SCHEMBL1651685 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2CXCR1CXCR2LMNA | |
| Ibuprofen SCHEMBL19439559 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2CXCR1CXCR2LMNA | |
| Ibuprofen SCHEMBL7037276 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2CXCR1CXCR2LMNA | |
| Dexibuprofen SCHEMBL30091137 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2CXCR1CXCR2LMNA | |
| Ibuprofen SCHEMBL3001 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2CXCR1CXCR2LMNA | |
| Dexibuprofen SCHEMBL43531 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2CXCR1CXCR2LMNA | |
| (R)-Ibuprophen SCHEMBL29057 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2CXCR1CXCR2LMNA | |
| Ibuprofen SCHEMBL19439560 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2CXCR1CXCR2LMNA | |
| Ibuprofen SCHEMBL8754799 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2CXCR1CXCR2LMNA | |
| Ibuprofen SCHEMBL5971382 | 0.98 | PTGS1 (0.96) | PTGS1PTGS2CXCR1CXCR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 556 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240075049-A1 | DRUGS, THERAPEUTIC COMBINATIONS AND METHODS FOR PREVENTING VIRAL AND MICROBIAL INFECTIONS AND THEIR SEQUELAE | TOPELIA AUST LTD ACN 652 771 670 (AU) | 2024-03-07 | — | — | US | claimed |
| EP-3060570-A1 | PANOTHENATE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Retrophin, Inc. (US) | 2016-08-31 | — | — | EP | claimed |
| WO-2015061792-A1 | PANOTHENATE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Retrophin, Inc. (US) | 2015-04-30 | — | — | WO | claimed |
| JP-2011526614-A | — | — | 2011-10-13 | — | — | JP | claimed |
| US-20110172460-A1 | PROCESS FOR THE MANUFACTURE OF RACEMIC 2-ARYL-PROPIONIC ACID | AESICA PHARMACEUTICALS LIMITED (GB) | 2011-07-14 | — | — | US | claimed |
| EP-2307335-A1 | PROCESS FOR THE MANUFACTURE OF RACEMIC 2-ARYL-PROPIONIC ACID | Aesica Pharmaceuticals Ltd. (GB) | 2011-04-13 | — | — | EP | claimed |
| EP-1732891-A4 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS INC (US) | 2009-05-06 | — | — | EP | claimed |
| WO-2005087728-A9 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS INC (US) | 2007-04-26 | — | — | WO | claimed |
| CN-1953964-A | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2007-04-25 | — | — | CN | claimed |
| WO-2007026240-A1 | SUNSCREEN AND COSMETIC COMPOSITIONS FOR PROPHYLAXIS OR TREATMENT OF SKIN CANCERS | MEDICAL THERAPIES LIMITED (AU) | 2007-03-08 | — | — | WO | claimed |
| EP-0615439-A1 | SLOW-RELEASE IBUPROFEN-CONTAINING MEDICAMENT AND ITS USE. | ALFATEC PHARMA GMBH (DE) | 1994-09-21 | — | — | EP | claimed |
| WO-1993010760-A1 | SLOW-RELEASE IBUPROFEN-CONTAINING MEDICAMENT AND ITS USE | ALFATEC-PHARMA GMBH (DE) | 1993-06-10 | — | — | WO | claimed |
| EP-0521344-A2 | Soluble salts of ibuprofen and naproxen with N-(2-hydroxyethyl) pyrrolidine and pharmaceutic compositions containing said salts | ALTERGON S.A. (CH) | 1993-01-07 | — | — | EP | claimed |
| EP-0348683-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING IBUPROFEN IN COMBINATION WITH A PIPERIDINOALKANOL ANTIHISTAMINE | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-10-30 | — | — | EP | claimed |
| EP-0413171-A1 | Strong analgesic composition and process for its preparation | Dolorgiet GmbH & Co. KG (DE) | 1991-02-20 | — | — | EP | claimed |
| EP-0383162-A1 | Use of a mixture of active substances in the treatment of rheumatic diseases | CASSELLA Aktiengesellschaft (DE) | 1990-08-22 | — | — | EP | claimed |
| EP-0313305-A2 | Photoprotection compositions comprising chelating agents | THE PROCTER & GAMBLE COMPANY (US) | 1989-04-26 | — | — | EP | claimed |
| EP-0260241-A1 | A new system for administration of liposomes to mammals | Aktiebolaget Draco (SE) | 1988-03-16 | — | — | EP | claimed |
| EP-0257288-A1 | Stabilized liquid analgesic compositions | ORATECH PHARMACEUTICAL DEVELOPMENT CORPORATION (US) | 1988-03-02 | — | — | EP | claimed |
| WO-1984000487-A1 | IMPROVED ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING IBUPROFEN AND METHOD OF USING SAME | RICHARDSON VICKS INC (US) | 1984-02-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172460-A1 | PROCESS FOR THE MANUFACTURE OF RACEMIC 2-ARYL-PROPIONIC ACID | SRR, GABBR2, GRHPR | PTGS1 2735/4885PTGS2 1940/4885CXCR1 4734/4885 |
| US-20240075049-A1 | DRUGS, THERAPEUTIC COMBINATIONS AND METHODS FOR PREVENTING VIRAL AND MICROBIAL INFECTIONS AND THEIR SEQUELAE | ACE, ACHE, SARS1 | PTGS1 1947/4885PTGS2 2108/4885CXCR1 2261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.